 The purpose of the present study is to compare the safety and efficacy of up to 2 injections of NKA given 3 to 6 months apart maximum in subjects who are randomized to receive their first treatment as soon as the NKA product is made available versus subjects who are randomized to undergo contemporaneous, standard-of-care treatment for CKD during the first 12 18 months prior to receiving up to 2 injections of NKA. 